Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.73 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.73 |
| ▸ | MET | P08581 | 14/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 5/20 | 0.55 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.55 |
| ▸ | MERTK | Q12866 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26317365 | 0.93 | RIPK3 (0.74) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL25364760 | 0.90 | RIPK3 (0.76) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL26317345 | 0.90 | RIPK3 (0.75) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL25366910 | 0.90 | RIPK3 (0.75) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL25367903 | 0.89 | MET (0.67) | RIPK3RIPK1RIPK2METAXL | |
| SCHEMBL26317391 | 0.89 | RIPK3 (0.72) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL26034229 | 0.88 | RIPK3 (0.73) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL30530993 | 0.88 | RIPK3 (0.73) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL26317418 | 0.84 | RIPK3 (0.77) | RIPK3RIPK1RIPK2METCYP3A4 | |
| SCHEMBL26317381 | 0.83 | RIPK3 (0.77) | RIPK3RIPK1RIPK2METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | RIPK3 1229/4885RIPK1 1682/4885RIPK2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.